Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
In humans and some other primates, the *L-gulono-γ-lactone oxidase* (GULO) gene exists as a pseudogene (GULOP), meaning it is a remnant of an ancestral gene that has lost its ability to encode a functional enzyme due to mutations such as insertions, deletions, and premature stop codons[3][4][1]. In other species, the active enzyme catalyzes the terminal step in vitamin C biosynthesis, converting L-gulonolactone to ascorbic acid (vitamin C)[2]. As a result of GULOP pseudogenization, humans cannot synthesize vitamin C and must obtain it from the diet, explaining the susceptibility to scurvy when dietary vitamin C is insufficient[3][4][1]. The gene is located on chromosome 8p21.3, is approximately 32-42 kb in size, and contains several nonfunctional exons[3]. There is no evidence that GULOP expresses a protein or regulatory product in humans, and no drugs target this locus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-gulono-γ-lactone oxidase pseudogene (GULOP).